Aim: Evaluation of biological characteristics of 13 identified proteins of patients with cirrhotic liver disease is the main aim of this research.
Background: In clinical usage, liver biopsy remains the gold standard for diagnosis of hepatic fibrosis. Evaluation and confirmation of liver fibrosis stages and severity of chronic diseases require a precise and noninvasive biomarkers. Since the early detection of cirrhosis is a clinical problem, achieving a sensitive, specific and predictive novel method based on biomarkers is an important task.
Methods: Essential analysis, such as gene ontology (GO) enrichment and protein-protein interactions (PPI) was undergone EXPASy, STRING Database and DAVID Bioinformatics Resources query.
Results: Based on GO analysis, most of proteins are located in the endoplasmic reticulum lumen, intracellular organelle lumen, membrane-enclosed lumen, and extracellular region. The relevant molecular functions are actin binding, metal ion binding, cation binding and ion binding. Cell adhesion, biological adhesion, cellular amino acid derivative, metabolic process and homeostatic process are the related processes. Protein-protein interaction network analysis introduced five proteins (fibroblast growth factor receptor 4, tropomyosin 4, tropomyosin 2 (beta), lectin, Lectin galactoside-binding soluble 3 binding protein and apolipoprotein A-I) as hub and bottleneck proteins.
Conclusion: Our result indicates that regulation of lipid metabolism and cell survival are important biological processes involved in cirrhosis disease. More investigation of above mentioned proteins will provide a better understanding of cirrhosis disease.
Schuppan D, Afdhal NH. Liver cirrhosis. Lancet. 2008;371(9615):838-51.
Bosch FX, Ribes J, Borras J. Epidemiology of primary liver cancer. Semin Liver Dis. 1999;19(3):271-85.
Mann RE, Smart RG, Govoni R. The epidemiology of alcoholic liver disease. Alcohol Res Health. 2003;27(3):209-19.
Friedman SL. Hepatic stellate cells: protean, multifunctional, and enigmatic cells of the liver. Physiol Rev. 2008;88(1):125-72.
Gray J, Chattopadhyay D, Beale GS, Patman GL, Miele L, King BP, et al. A proteomic strategy to identify novel serum biomarkers for liver cirrhosis and hepatocellular cancer in individuals with fatty liver disease. BMC cancer. 2009;9(271):1471-2407.
Simonetti RG, Camma C, Fiorello F, Politi F, D'Amico G, Pagliaro L. Hepatocellular carcinoma. A worldwide problem and the major risk factors. Dig Dis Sci. 1991;36(7):962-72.
Heidelbaugh JJ, Bruderly M. Cirrhosis and chronic liver failure: part I. Diagnosis and evaluation. Am Fam Physician. 2006;74(5):756-62.
Qi SW, Tu ZG, Peng WJ, Wang LX, Ou-Yang X, Cai AJ, et al. (1)H NMR-based serum metabolic profiling in compensated and decompensated cirrhosis. World J Gastroenterol. 2012;18(3):285-90.
Zali H, Rezaei-Tavirani M, Azodi M. Gastric cancer: prevention, risk factors and treatment. Gastroenterology and Hepatology from bed to bench. 2011;4(4):175.
Xue R, Dong L, Wu H, Liu T, Wang J, Shen X. Gas chromatography/mass spectrometry screening of serum metabolomic biomarkers in hepatitis B virus infected cirrhosis patients. Clin Chem Lab Med. 2009;47(3):305-10.
Mas VR, Maluf DG, Archer KJ, Yanek K, Bornstein K, Fisher RA. Proteomic analysis of HCV cirrhosis and HCV-induced HCC: identifying biomarkers for monitoring HCV-cirrhotic patients awaiting liver transplantation. Transplantation. 2009;87(1):143-52.
Molleken C, Sitek B, Henkel C, Poschmann G, Sipos B, Wiese S, et al. Detection of novel biomarkers of liver cirrhosis by proteomic analysis. Hepatology. 2009;49(4):1257-66.
Rodrigo L, Alvarez V, Rodriguez M, Perez R, Alvarez R, Coto E. N-acetyltransferase-2, glutathione S-transferase M1, alcohol dehydrogenase, and cytochrome P450IIE1 genotypes in alcoholic liver cirrhosis: a case-control study. Scand J Gastroenterol. 1999;34(3):303-7.
Kim JW, Ye Q, Forgues M, Chen Y, Budhu A, Sime J, et al. Cancer-associated molecular signature in the tissue samples of patients with cirrhosis. Hepatology. 2004;39(2):518-27.
Hannivoort RA, Hernandez-Gea V, Friedman SL. Genomics and proteomics in liver fibrosis and cirrhosis. Fibrogenesis Tissue Repair. 2012;5(1):1755-536.
Zamanian–Azodi M, Rezaei–Tavirani M, Hasanzadeh H, Rad SR, Dalilan S. Introducing biomarker panel in esophageal, gastric, and colon cancers; a proteomic approach. Gastroenterology and Hepatology from bed to bench. 2015;8(1):6.
Safari-Alighiarloo N, Taghizadeh M, Rezaei-Tavirani M, Goliaei B, Peyvandi AA. Protein-protein interaction networks (PPI) and complex diseases. Gastroenterol Hepatol Bed Bench. 2014;7(1):17-31.
Huang da W, Sherman BT, Lempicki RA. Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources. Nat Protoc. 2009;4(1):44-57.
Ghamari E, Zali H, Rezaie Tavirani M, Hesami Takalu S, Goshadrou F, Ahmadi N, et al. Proteomic study in the rat hippocampus as a measure of human Alzheimer’s disease. Koomesh. 2015;16(4):611-20.
Liu H, Hu ZZ, Wu CH. DynGO: a tool for visualizing and mining of Gene Ontology and its associations. BMC Bioinformatics. 2005;6:201.
Lee JS, Katari G, Sachidanandam R. GObar: a gene ontology based analysis and visualization tool for gene sets. BMC Bioinformatics. 2005;6:189.
Huang DW, Sherman BT, Tan Q, Collins JR, Alvord WG, Roayaei J, et al. The DAVID Gene Functional Classification Tool: a novel biological module-centric algorithm to functionally analyze large gene lists. Genome Biol. 2007;8(9).
Huang DW, Sherman BT, Lempicki RA. Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources. Nature protocols. 2008;4(1):44-57.
Da Wei Huang BTS, Stephens R, Baseler MW, Lane HC, Lempicki RA. DAVID gene ID conversion tool. Bioinformation. 2008;2(10):428.
Huang DW, Sherman BT, Lempicki RA. Bioinformatics enrichment tools: paths toward the comprehensive functional analysis of large gene lists. Nucleic acids research. 2009;37(1):1-13.
Zali H, Zamanian-Azodi M, Tavirani MR, Baghban AA-z. Protein Drug Targets of Lavandula angustifolia on treatment of Rat Alzheimer's Disease. Iranian journal of pharmaceutical research: IJPR. 2015;14(1):291.
Franceschini A, Szklarczyk D, Frankild S, Kuhn M, Simonovic M, Roth A, et al. STRING v9.1: protein-protein interaction networks, with increased coverage and integration. Nucleic Acids Res. 2013;41(Database issue):29.
Zamanian-Azodi M, Rezaei-Tavirani M, Rahmati-Rad S, Hasanzadeh H, Rezaei Tavirani M, Seyyedi SS. Protein-Protein Interaction Network could reveal the relationship between the breast and colon cancer. Gastroenterol Hepatol Bed Bench. 2015;8(3):215-24.
von Mering C, Huynen M, Jaeggi D, Schmidt S, Bork P, Snel B. STRING: a database of predicted functional associations between proteins. Nucleic Acids Res. 2003;31(1):258-61.
Farazi PA, DePinho RA. Hepatocellular carcinoma pathogenesis: from genes to environment. Nat Rev Cancer. 2006;6(9):674-87.
Tipney H, Hunter L. An introduction to effective use of enrichment analysis software. Hum Genomics. 2010;4(3):202-6.
Vanni E, Bugianesi E, Kotronen A, De Minicis S, Yki-Jarvinen H, Svegliati-Baroni G. From the metabolic syndrome to NAFLD or vice versa? Dig Liver Dis. 2010;42(5):320-30.
Larter CZ, Chitturi S, Heydet D, Farrell GC. A fresh look at NASH pathogenesis. Part 1: the metabolic movers. J Gastroenterol Hepatol. 2010;25(4):672-90.
Malaguarnera M, Di Rosa M, Nicoletti F, Malaguarnera L. Molecular mechanisms involved in NAFLD progression. J Mol Med. 2009;87(7):679-95.
Rombouts K, Marra F. Molecular mechanisms of hepatic fibrosis in non-alcoholic steatohepatitis. Dig Dis. 2010;28(1):229-35.
Lewis JR, Mohanty SR. Nonalcoholic fatty liver disease: a review and update. Dig Dis Sci. 2010;55(3):560-78.
Gonzalez-Angulo AM, Ferrer-Lozano J, Stemke-Hale K, Sahin A, Liu S, Barrera JA, et al. PI3K pathway mutations and PTEN levels in primary and metastatic breast cancer. Molecular cancer therapeutics. 2011;10(6):1093-101.
Dharancy S, Louvet A, Hollebecque A, Desreumaux P, Mathurin P, Dubuquoy L. [Nuclear receptor PPAR and hepatology: pathophysiological and therapeutical aspects]. Gastroenterol Clin Biol. 2008;32(3):339-50.
Peyrou M, Ramadori P, Bourgoin L, Foti M. PPARs in Liver Diseases and Cancer: Epigenetic Regulation by MicroRNAs. PPAR Res. 2012;757803:13.
Sheu MJ, Hsieh MJ, Chiang WL, Yang SF, Lee HL, Lee LM, et al. Fibroblast growth factor receptor 4 polymorphism is associated with liver cirrhosis in hepatocarcinoma. PLoS ONE. 2015;10(4).
Gressner OA, Weiskirchen R, Gressner AM. Biomarkers of hepatic fibrosis, fibrogenesis and genetic pre-disposition pending between fiction and reality. J Cell Mol Med. 2007;11(5):1031-51.
Mona Zamanian-Azodi MR-T, Sara Rahmati-Rad, Majid Rezaei-Tavirani. Ethanol and cancer induce similar changes on protein expression pattern of human fibroblast cells. Iranian Journal of Pharmaceutical Research. Accepted.
Nakagawa H, Maeda S. Molecular mechanisms of liver injury and hepatocarcinogenesis: focusing on the role of stress-activated MAPK. Patholog Res Int. 2012;172894(10):14.
Jaeschke H. Cellular adhesion molecules: regulation and functional significance in the pathogenesis of liver diseases. Am J Physiol. 1997;273(3 Pt 1):G602-11.
Waanders E, Van Krieken JH, Lameris AL, Drenth JP. Disrupted cell adhesion but not proliferation mediates cyst formation in polycystic liver disease. Mod Pathol. 2008;21(11):1293-302.
Dirchwolf M, Ruf AE. Role of systemic inflammation in cirrhosis: From pathogenesis to prognosis. World J Hepatol. 2015;7(16):1974-81.
McIntyre N. Plasma lipids and lipoproteins in liver disease. Gut. 1978;19(6):526-30.
Mostafa Rezaei-Tavirani MZ-A, Sepideh Rajabi , Ali Masoudi-Nejad , Mohammad Rostami-Nejad , Sara Rahmatirad Protein Clustering and Interactome Analysis in Parkinson and Alzheimer's Diseases. Arch Iran Med 2016;19(2):In press.